[1]周强,杨斌,周志明,等.心脏移植术后并发心脏移植物血管病变研究进展[J].新乡医学院学报,2022,39(11):1074-1078.[doi:10.7683/xxyxyxb.2022.11.015]
　ZHOU Qiang,YANG Bin,ZHOU Zhiming,et al.Research progress of cardiac allograft vasculopathy after heart transplantation[J].Journal of Xinxiang Medical University,2022,39(11):1074-1078.[doi:10.7683/xxyxyxb.2022.11.015]
点击复制

心脏移植术后并发心脏移植物血管病变研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年11
页码:
1074-1078
栏目:
综述
出版日期:
2022-11-05

文章信息/Info

Title:
Research progress of cardiac allograft vasculopathy after heart transplantation
作者:
周强1; 杨斌2; 周志明2; 王琰2
(1.新乡医学院研究生处，河南　新乡　453003；2.郑州市第七人民医院心脏移植中心，河南　郑州　450016）
Author(s):
ZHOU Qiang1; YANG Bin2; ZHOU Zhiming2; WANG Yan2
(1.Department of Graduate Studies Division,Xinxiang Medical University,Xinxiang 453003,Henan Province,China;2.Department of Heart Transplantation Centre,Zhengzhou NO.7 People′s Hospital,Zhengzhou 450016,Henan Province,China)
关键词:
心脏移植物血管病变; 同种异体移植排斥; 冠状动脉内成像
Keywords:
cardiac allograft vasculopathy; allograft rejection; intracoronary imaging
分类号:
R541
DOI:
10.7683/xxyxyxb.2022.11.015
文献标志码:
A
摘要:
心脏移植物血管病变（CAV）是影响接受心脏移植患者远期生存的主要因素。目前，针对心脏移植术后并发CAV发病机制的研究正在不断深入，而心血管系统成像技术的发展也促进了广大科研和医疗工作者对其发病过程的直接了解。诊断方式的创新推动了相关生物标志物的普及，同时，药理学研究方向的不断突破也改善了CAV的预后。本文就心脏移植术并发CAV的研究进展进行综述，旨在增强临床工作者对CAV发病机制、诊断技术和防治措施的认识，减少CAV的发生，提高心脏移植患者远期生存率。
Abstract:
Cardiac allograft vasculopathy (CAV) is the main factor affecting the long-term survival of patients receiving heart transplantation.At present,the pathogenesis of CAV after heart transplantation is being deepened and developed,and the development of cardiovascular imaging technology has also promoted the scientific research and medical workers to have a direct understanding on its pathogenesis.Innovations in diagnostic methods have driven the popularity of relevant biomarkers,while the continuous breakthrough of pharmacological research direction also improves the prognosis of CAV.This article reviews the research progress of CAV after heart transplantation,in order to enhance the understanding of clinical workers on the pathogenesis,diagnostic techniques and preventive measures of CAV,reduce the occurrence of CAV,and improve the long-term survival rate of heart transplant patients.

参考文献/References:

［1］　SUN Y,WANG Z,ZHANG J,et al.Current status of and opinions on heart transplantation in China［J］.Curr Med Sci,2021,41(5):841-846.
［2］　中华医学会器官移植学分会.中国心脏移植术后并发症诊疗规范(2019版)［J/CD］.中华移植杂志(电子版),2019,13(1):21-23.DOI:10.3877/cma.j.issn.1674-3903.2019.01.005.
DIVISION OF ORGAN TRANSPLANTATION,CHINESE MEDICAL ASSOCIATION.Chinese code of practice for the diagnosis and treatment of postoperative complications of heart transplantation (2019 edition)［J/CD］.Chin J Transplant (Electronic Version),2019,13(1):21-23.DOI:10.3877/cma.j.issn.1674-3903.2019.01.005.
［3］　中华医学会器官移植学分会.中国心脏移植术后随访技术规范(2019版)［J/CD］.中华移植杂志：电子版,2019,13(1):24-27.DOI:10.3877/cma.j.issn.1674-3903.2019.01.006.
DIVISION OF ORGAN TRANSPLANTATION,CHINESE MEDICAL ASSOCIATION.Technical specifications for postoperative follow-up of heart transplantation in China (2019 edition)［J/CD］.Chin J Transplant:Electronic Version,2019,13(1):24-27.DOI:10.3877/cma.j.issn.1674-3903.2019.01.006.
［4］　MEHRA M R,CRESPO-LEIRO M G,DIPCHAND A,et al.International society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010［J］.J Heart Lung Transplant,2010,29(7):717-727.
［5］　NIKOLOVA A P,KOBASHIGAWA J A.Cardiac allograft vasculopathy:the enduring enemy of cardiac transplantation［J］.Transplantation,2019,103(7):1338-1348.
［6］　POBER J S,CHIH S,KOBASHIGAWA J,et al.Cardiac allograft vasculopathy:current review and future research directions［J］.Cardiovasc Res,2021,117(13):2624-2638.
［7］　TREMBLAY-GRAVEL M,RACINE N,DE DENUS S,et al.Changes in outcomes of cardiac allograft vasculopathy over 30 years following heart transplantation［J］.JACC:Heart Fail,2017,5(12):891-901.
［8］　MALLAH S I,ATALLAH B,MOUSTAFA F,et al.Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy［J］.Prog Cardiovasc Dis,2020,63(3):194-209.
［9］　PIGHI M,GRATTA A,MARIN F,et al.“Cardiac allograft vasculopathy:pathogenesis,diagnosis and therapy”［J］.Transplantat Rev,2020,34(4):100569.
［10］　LEE F,NAIR V,CHIH S.Cardiac allograft vasculopathy:insights on pathogenesis and therapy［J］.Clin Transplant,2020,34(3):e13794.
［11］　ABELE S,SPRIEWALD B M,RAMSPERGER-GLEIXNER M,et al.Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts［J］.Transplantation,2009,87(2):207-216.
［12］　ABELE S,WEYAND M,WOLLIN M,et al.Clopidogrel reduces the development of transplant arteriosclerosis［J］.J Thorac Cardiovasc Surg,2006,131(5):1161-1166.
［13］　MAEHARA T,KANEKO N,PERUGINO C A,et al.Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis［J］.J Clin Invest,2020,130(5):2451-2464.
［14］　GUSTAFSSON F,ANDREASSEN A K,ANDERSSON B,et al.Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients:long-term follow-up from the randomized SCHEDULE study［J］.Transplantation,2020,104(1):154-164.
［15］　ASLEH R,CLAVELL A L,PEREIRA N L,et al.Incidence of malignancies in patients treated with sirolimus following heart transplantation［J］.Am Coll Cardiol,2019,73(21):2676-2688.
［16］　JANKOWSKA GAN E,AGASHE V V,LEMA D A,et al.Donor HLA-DR drives the development of de novo autoimmunity following lung and heart transplantation［J］.Transplant Direct,2020,6(10):e607.
［17］　BERGMARK B A,ZELNIKER T A,KIM M,et al.Early aspirin use,allograft rejection,and cardiac allograft vasculopathy in heart transplantation［J］.Clin Transplant,2021,35(10):e14424.
［18］　ZHANG Z,ZHANG N,SHI J,et al.Allograft or recipient ST2 deficiency oppositely affected cardiac allograft vasculopathy via differentially altering immune cells infiltrationImage［J］.Front Immunol,2021,12:657803.
［19］　LOUPY A,COUTANCE G,BONNET G,et al.Identification and characterization of trajectories of cardiac allograft vasculopathy after heart transplantation［J］.Circulation,2020,141(24):1954-1967.
［20］　MALLAH S I,ATALLAH B,MOUSTAFA F,et al.Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy［J］.Prog Cardiovasc Dis,2020,63(3):194-209.
［21］　PICO S,OLIVEIRA-SANTOS M,BATISTA M,et al.Cardiac allograft vasculopathy:incidence and predictors in a single-center cohort［J］.Rev Port Cardiol (Engl Ed),2020,39(4):205-212.
［22］　KLIMCZAK-TOMANIAK D,ROEST S,BRUGTS J J,et al.The association between cytomegalovirus infection and cardiac allograft vasculopathy in the era of antiviral valganciclovir prophylaxis［J］.Transplantation,2020,104(7):1508-1518.
［23］　MCGOVERN E,HOSKING M C K,BALBACID E,et al.Optical coherence tomography for the early detection of coronary vascular changes in children and adolescents after cardiac transplantation:findings from the international pediatric OCT registry［J］.JACC Cardiovasc Imaging,2019,12(12):2492-2501.
［24］　PRADA-DELGADO O,ESTVEZ-LOUREIRO R,PANIAGUA-MARTN M J,et al.Prevalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature［J］.J Heart Lung Transplant,2020,31(3):332-333.
［25］　SATO T,CHENG R,AZARBAL B,et al.Combined heart and kidney transplantation:is there a protective effect against cardiac allograft vasculopathy using intravascular ultrasound?［J］.J Heart Lung Transplant,2019,38(9):956-962.
［26］　CLEMMENSEN T S,HOLM N R,EISKJR H,et al.Layered fibrotic plaques are the predominant component in cardiac allograft vasculopathy［J］.JACC Cardiovasc Imaging,2017,10(7):773-784.
［27］　CLEMMENSEN T S,HOLM N R,EISKJAER H,et al.Detection of early changes in the coronary artery microstructure after heart transplantation:a prospective optical coherence tomography study ［J］.J Heart Lung Transplant,2018,37(4):486-495.
［28］　SZCZUROWSKA A,BANASIK M,KURCZ J,et al.Intra-arterial computed tomography angiography with ultra-low volume of iodine contrast and stent implantation in transplant renal artery stenosis in terms of contrast-induced kidney injury:a preliminary report ［J］.Pol J Radiol,2020,85:e174-e177.
［29］　FOLDYNA B,SANDRI M,LUECKE C,et al.Quantitative coronary computed tomography angiography for the detection of cardiac allograft vasculopathy［J］.Eur Radiol,2020,30(8):4317-4326.
［30］　ELKARYONI A,SHEASHA G A,ALTIBI A M,et al.Diagnostic accuracy of dobutamine stress echocardiography in the detection of cardiac allograft vasculopathy in heart transplant recipients:a systematic review and meta-analysis study［J］.Echocardiography,2019,36(3):528-536
［31］　KHAN R,JANG I K.Evaluation of coronary allograft vasculopathy using multi-detector row computed tomography:a systematic review［J］.Eur J Cardiothorac Surg,2012,41(2):415-422.
［32］　SCIACCALUGA C,GHIONZOLI N,MANDOLI G,et al.The role of non-invasive imaging modalities in cardiac allograft vasculopathy:an updated focus on current evidences［J］.Heart Fail Rev,2022,27(4):1235-1246.
［33］　ELAMRAGY A A,ABDELWAHAB M A,ELREMISY D R,et al.Additional diagnostic accuracy of global longitudinal strain at peak dobutamine stress in patients with moderate pretest probability of coronary artery disease［J］.Echocardiography,2020,37(8):1222-1232.
［34］　KHEMKA A,SAWADA S G.Dobutamine echocardiography for assessment of viability in the current era［J］.Curr Opin Cardiol,2019,34(5):484-489.
［35］　WIEFELS C,ALMUFLEH A,YAO J,et al.Prognostic utility of longitudinal quantification of PET myocardial blood flow early post heart transplantation［J］.J Nucl Cardiol,2022,29(2):712-723.
［36］　KONERMAN M C,LAZARUS J J,WEINBERG R L,et al.Reduced myocardial flow reserve by positron emission tomography predicts cardiovascular events after cardiac transplantation［J］.Circ Heart Fail,2018,11(6):e004473.
［37］　MALLAH S I,ATALLAH B,MOUSTAFA F,et al.Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy［J］.Prog Cardiovasc Dis,2020,63(3):194-209.
［38］　SZCZUREK W,GASIOR M,SKRZYPEK M,et al.Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients［J］.Am J Transplant,2020,20(10):2857-2866.
［39］　SPITALERI G,FARRERO TORRES M F,SABATINO M,et al.The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation［J］.Expert Opin Pharmacother,2020,21(11):1367-1376.
［40］　LEE H,LI C,ZHANG Y,et al.Caveolin-1 selectively regulates microRNA sorting into microvesicles after noxious stimuli［J］.J Exp Med,2019,216(9):2202-2220.

更新日期/Last Update: 2022-11-05